Taori Suchet, Wei Zhishuo, Hadjipanayis Constantinos G, Niranjan Ajay, Lunsford L Dade
School of Medicine, University of Pittsburgh Medical Center, 200 Lothrop Street, Pittsburgh, PA, 15213, USA.
Department of Neurological Surgery, University of Pittsburgh Medical Center, Pittsburgh, PA, USA.
J Neurooncol. 2025 Jun;173(2):429-438. doi: 10.1007/s11060-025-05000-5. Epub 2025 Mar 31.
Stereotactic radiosurgery (SRS) for the management of small and medium-sized intracranial meningiomas is well defined. However, limited studies evaluating long-term outcomes following SRS for large-volume meningiomas (LVMs) exist. Here, we report a large single-institution experience in using upfront single-session SRS to manage LVMs.
This retrospective review included 112 patients (83 female, 74%) managed with single-session SRS for LVMs (> 10 cc) between 1987 and 2022. Exclusion criteria consisted of prior meningioma surgical resection or follow-up < 2 years. Tumors were classified as supratentorial (35%) or skull-base (65%). The median tumor volume was 13 cc (range: 10-24.7), and the median margin dose was 12 Gy (range: 10-15). Overall, 101 (90%) patients were neurologically symptomatic at SRS.
The median follow-up was 106 months (range: 24-307). Sixteen (14%) LVMs demonstrated tumor progression at a median time of 43 months (range: 7-181) following SRS. Local tumor control (LTC) rates at 3-years, 5-years, and 10-years were 98% (95%CI: 91-99), 97% (95% CI: 94-100) and 88% (95% CI: 80-96), respectively. Tumor volume > 17 cc (HR: 3.26, 95% CI: 1.17-9.08, p = 0.023) was significantly associated with worsened LTC. Seven (6%) patients developed peritumoral edema adverse radiation effects (AREs) at a median time of 35 months (range: 4-182) following SRS. Meningiomas located in supratentorial regions (OR: 1.11, 95% CI: 1.01-1.22, p = 0.031), as compared to skull base tumors, had a significantly greater risk of peritumoral edema ARE development.
In this select patient cohort, upfront single-session SRS provides durable long-term LTC and minimizes ARE risk for patients with LVMs.
立体定向放射外科(SRS)用于治疗中小型颅内脑膜瘤已有明确的定义。然而,评估SRS治疗大体积脑膜瘤(LVM)长期疗效的研究有限。在此,我们报告了在一家单一机构使用 upfront 单次 SRS 治疗 LVM 的大量经验。
这项回顾性研究纳入了1987年至2022年间接受单次SRS治疗LVM(>10 cc)的112例患者(83例女性,占74%)。排除标准包括既往有脑膜瘤手术切除史或随访时间<2年。肿瘤分为幕上型(35%)或颅底型(65%)。肿瘤体积中位数为13 cc(范围:10-24.7),边缘剂量中位数为12 Gy(范围:10-15)。总体而言,101例(90%)患者在接受SRS时存在神经症状。
中位随访时间为106个月(范围:24-307)。16例(14%)LVM在SRS后中位43个月(范围:7-181)出现肿瘤进展。3年、5年和10年的局部肿瘤控制(LTC)率分别为98%(95%CI:91-99)、97%(95%CI:94-100)和88%(95%CI:80-96)。肿瘤体积>17 cc(HR:3.26,95%CI:1.17-9.08,p = 0.023)与LTC恶化显著相关。7例(6%)患者在SRS后中位35个月(范围:4-182)出现瘤周水肿这一不良放射效应(ARE)。与颅底肿瘤相比,幕上区域的脑膜瘤发生瘤周水肿ARE的风险显著更高(OR:1.11,95%CI:1.01-1.22,p = 0.031)。
在这个特定的患者队列中, upfront 单次SRS为LVM患者提供了持久的长期LTC,并将ARE风险降至最低。